FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.
about
The systemic nature of CKD.α-Klotho expression determines nitric oxide synthesis in response to FGF-23 in human aortic endothelial cellsFGF23/FGFR4-mediated left ventricular hypertrophy is reversible.Fibroblast growth factor 23 and acute kidney injury.Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motifPhosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio Is a Useful Marker of Atherosclerosis in Early-Stage Chronic Kidney Disease.Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus.Skeletal Muscle, but not Cardiovascular Function, Is Altered in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets.Association of Endothelial and Mild Renal Dysfunction With the Severity of Left Ventricular Hypertrophy in Hypertensive Patients.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice.Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes.Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative reviewArterial Stiffness: A Novel Risk Factor for Kidney Injury Progression?The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.Endothelial dysfunction and vascular disease - a 30th anniversary update.Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.Extrarenal effects of FGF23.Heart failure with preserved ejection fraction: a nephrologist-directed primer.Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells.αKlotho and Chronic Kidney Disease.Intact FGF23 and α-Klotho during acute inflammation/sepsis in CKD patients.Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.Restoration of Endothelial Function in Pparα (-/-) Mice by Tempol.Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis.Decreased Expression of Thrombomodulin in Endothelial Cells by Fibroblast Growth Factor-23/α-Klotho.Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis.Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis.Pleiotropic Actions of FGF23.Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease.Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II
P2860
Q30234695-62D68B71-4244-4C01-A0CF-5FBC0AC2D14FQ33626706-73975225-550A-49FE-83BE-86813F8D8661Q33694566-60737CF0-FA85-44B0-8344-25486D1E57E9Q35690579-0B1DD522-EFFB-4AB5-A263-91C9053F3F18Q35850452-33C6B4C0-5FDB-4840-A691-975DD7C300AAQ35998095-9B140B88-7668-4C97-AB54-638652DB61B0Q36098749-236642D6-5CF8-42C1-915F-113BBC42378AQ36520483-D846C635-24C9-4D3E-B252-A723C7B1D191Q36899883-A81E84C6-524E-4F5A-95BE-AF622F50BEA8Q36950146-DCAAC892-79B1-4D0B-82F3-AED0FF8A3737Q36983860-90EC612F-CD91-4C07-AC50-35A9B4635E37Q37080167-CC2818E9-6BCC-48A9-82B7-C373497A934AQ37307040-1A15C29D-7596-4416-8080-671DA74D1CF4Q37695914-B23E2836-7981-4066-B98D-31625C6C3487Q38357928-75694F23-654D-4CFF-85C1-ED7B8C848CE7Q38644586-02CF9584-6C7C-464F-B3B7-9A94BB1B1E9AQ38680112-3C3E9853-E829-4C1E-B51C-BADFDE3614A3Q38727741-FFF1AFED-81E6-4777-9A5B-3EF46712A61DQ38972469-5BDB03DE-3296-402B-A1E2-7B8A7CCC2CB4Q39301622-4094861D-0DFB-497A-BA2E-32422E156F42Q39569165-A6B2E446-1613-4AC1-9743-9BF1592A5AA2Q39812781-ED368C51-C54C-4B24-BCFE-1BAF2D1B1E0BQ40846380-3A7AC43E-098A-4CB3-B8D1-08A8959A9B02Q41611152-222BD88F-90BD-48E1-A97B-3F702C0F83AEQ42787829-319F6DAB-278D-480D-B04D-E0EC2D3DBC27Q47368100-B5D6F781-C333-464F-8078-7CA920B60DA0Q48187797-3143B645-23BB-4520-BBC2-9D5653B6420CQ50067183-ED63A5D2-060F-435F-A7D7-B3B6E3D826CFQ51197552-3763071C-6697-430B-817E-CBFCC1150FF9Q54139850-AA0C3089-B589-4291-A882-ACD412906D91Q55442487-52C060AE-18A7-412B-8F67-6791B86BCD82Q58770788-00B65DE2-6CB3-41BE-A04F-B3C97B3DC1F4
P2860
FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
FGF23 directly impairs endothe ...... nitric oxide bioavailability.
@ast
FGF23 directly impairs endothe ...... nitric oxide bioavailability.
@en
FGF23 directly impairs endothe ...... nitric oxide bioavailability.
@nl
type
label
FGF23 directly impairs endothe ...... nitric oxide bioavailability.
@ast
FGF23 directly impairs endothe ...... nitric oxide bioavailability.
@en
FGF23 directly impairs endothe ...... nitric oxide bioavailability.
@nl
prefLabel
FGF23 directly impairs endothe ...... nitric oxide bioavailability.
@ast
FGF23 directly impairs endothe ...... nitric oxide bioavailability.
@en
FGF23 directly impairs endothe ...... nitric oxide bioavailability.
@nl
P2093
P2860
P1476
FGF23 directly impairs endothe ...... g nitric oxide bioavailability
@en
P2093
Darla L McCarthy
Dorothy R Daniel
Jason R Stubbs
Jon Andresen
Michael J Wacker
Shiqin Zhang
P2860
P304
P356
10.1152/AJPENDO.00264.2014
P577
2014-07-22T00:00:00Z